Navigation Links
Epizyme identifies novel opportunity for treatment of genetically defined human B-cell lymphomas
Date:11/15/2010

Cambridge, MA, November 15, 2010 - Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, today announced the publication of breakthrough new research in the Proceedings of the National Academy of Sciences (USA). The discovery, centered on the epigenetic enzyme EZH2, illuminates a clear path for the translation of basic science into targeted therapies for the safe and effective treatment of specific forms of human lymphomas. EZH2 is a histone methyltransferase (HMT), a class of enzymes that play an important role in regulating the activity of particular groups of genes that are involved in serious diseases, including cancer.

The paper describes how the development of two non-Hodgkin lymphomas - follicular lymphoma and germinal center B-cell like subtype of diffuse large B-cell lymphoma - requires the combined activities of both the wild-type and Tyr641 mutants of EZH2. This novel insight reinforces the development of targeted therapeutics for these patients, as it repudiates the previous supposition that the Tyr641 mutation resulted in a loss of EZH2 function.

Dr. Robert A. Copeland, EVP of R&D and CSO, said, "We believe this is the first example of a human disease that is reliant on the combined catalytic activity of both normal and disease-associated mutant enzymes. By targeting HMTs with clear genetic disease associations, such as EZH2, Epizyme takes a hypothesis-driven approach to development of personalized therapeutics for specific patient populations with high unmet needs. Our product platform enables the creation of novel, potent and selective small molecule HMT inhibitors."

"This paper is a novel, important and representative example of the rapidly growing understanding of the oncogenic role played by HMTs in many cancers. It highlights the promise of HMT inhibitors as novel therapeutics against these targets," said Professor Christopher T. Walsh, the Hamilton Kuhn Professor of Biological Chemistry and Molecular Pharmacology (BCMP) at Harvard Medical School and a member of Epizyme's Scientific Advisory Board.


'/>"/>

Contact: Jennifer Conrad
jconrad@macbiocom.com
781-235-3060
MacDougall Biomedical Communications, Inc.
Source:Eurekalert

Related biology technology :

1. Tool identifies infection clusters; rate of T cell drop not helpful in decision to start treating HIV
2. New Industry Research Identifies "Operational Gap" in Clinical Trial Portfolio Management
3. DNA2.0 Unlocks The Secrets Of Optimized Gene Design: Company Identifies Codon Choice Design Principles for Optimal Protein Expression
4. ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist
5. Magellan to Receive Frost & Sullivan 2009 North American Product Innovation Award; Three-Minute LeadCare(R) II Test Identifies Children with Lead Poisoning
6. New research identifies faster detection of viruses
7. Famed IT Investor and Director of 23andme Esther Dyson Identifies on IdeasProject.com Genetic Information as an Extremely Disruptive Force
8. Multinational deCODE Study Identifies New Link Between Inflammation and Heart Attack
9. Oligomerix, Inc. Awarded Phase II NIH Grant to Discover Novel Drugs for Alzheimers Disease
10. Novel metamaterial vastly improves quality of ultrasound imaging
11. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. ... STACS DNA as a Field Application Specialist. , “I am thrilled that Dr. ... STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings a ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
Breaking Biology Technology:
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
Breaking Biology News(10 mins):